Cancer is a major health concerns for European citizens. Thus, the main research aim of this Network for Optimized Astatine labeled Radiopharmaceuticals (NOAR) COST Action is to successfully demonstrate that one of the most promising radionuclides for Targeted Alpha Therapy (TAT), namely Astatine-211, can become the European standard for treatment of certain cancerous pathologies.

To this end, an efficient networking is essential among all European stakeholders interested in promoting Astatine-211 for medical applications.

NOAR COST Action brings together European and international excellence labs, Astatine-211 production centers, hospitals, industry and patient associations from more than 20 countries, thus covering the whole value chain of innovation: production, chemistry, radiochemistry, biology, preclinical and clinical research and delivery of radiopharmaceuticals to patients.

A European web portal will be created containing information for patients, practitioners, researchers, Industry and as a contact point for National and European patient associations.

The idea is to gather forces at the European level in order to implement actions to leverage hurdles to the development of this powerful radionuclide and to identify pathologies in which it will be particularly relevant.

A special emphasis will be given to train a new generation of young researchers and PhD students, promoting interdisciplinary competences through international and inter-sectoral mobility.

The long-term goal of this project is to make Astatine-211 technology available to all European citizens.

A european coomunity & a new model